Back

When should we start P2Y12 inhibitors in patients with an acute coronary syndrome?

28 August 2017 (08:31 - 08:52)
Organised by:
Congress Presentation Part of: Starting, stopping, and everything in between: recent data concerning dual antiplatelet therapy in ACS Thrombosis and platelets ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Gilles Montalescot

Sorbonne University, Paris (France)

3 More presentations in this session

Presentation thumbnail
Role of intravenous antiplatelet drugs in acute coronary syndromes
Professor D. Angiolillo (Jacksonville, US)
Slides Video
Presentation thumbnail
How to manage ACS patients who require oral anticoagulation?
Professor J. ten Berg (Nieuwegein, NL)
Slides Video
Presentation thumbnail
How long is long enough? When to stop DAPT after an acute coronary syndrome?
Doctor L. Mauri (Boston, US)
Slides Video

Access the full session

Session thumbnail
Starting, stopping, and everything in between: recent data concerning dual antiplatelet therapy in ACS

The Event

Event poster

ESC Congress 2017

28 August 2017 08:31 CET
You may be interested in
thumbnail
Congress Presentation
Impact of P2Y12 inhibitor pretreatment before coronary angiography in high risk NSTE-ACS: A comparative cohort analysis
21 March 2026
thumbnail
Congress Session
Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more
28 August 2023
thumbnail
Webinar
Acute LDL-C reduction during and immediately after ACS: is it prime time?
7 February 2022
thumbnail
Congress Presentation
Injectable and intravenous P2Y12 inhibitors in patients with acute myocardial infarction.
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources